Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) EBITDA Margin (2016 - 2025)

Immucell's EBITDA Margin history spans 16 years, with the latest figure at 25.22% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 4858.0% year-over-year to 25.22%; the TTM value through Dec 2025 reached 0.78%, up 89.0%, while the annual FY2025 figure was 0.78%, 92.0% up from the prior year.
  • EBITDA Margin reached 25.22% in Q4 2025 per ICCC's latest filing, down from 0.36% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 23.36% in Q4 2024 to a low of 65.46% in Q1 2023.
  • Average EBITDA Margin over 5 years is 10.41%, with a median of 9.12% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -7497bps in 2023, then surged 6132bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 2.67% in 2021, then tumbled by -1664bps to 41.77% in 2022, then skyrocketed by 47bps to 21.94% in 2023, then surged by 206bps to 23.36% in 2024, then tumbled by -208bps to 25.22% in 2025.
  • Per Business Quant, the three most recent readings for ICCC's EBITDA Margin are 25.22% (Q4 2025), 0.36% (Q3 2025), and 8.84% (Q2 2025).